Drug Database
Back to search

Belgium· BE-AMP-SAM326812-00

Piperacilline-Tazobactam EG 2 g - 0.25 g

A piperacillin und beta-lactamase-inhibitor product containing tazobactam sodium, registered in Belgium by EG. The same ATC class is registered in 12 of our 19 countries.

ATC J01CR05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedPiperacilline-Tazobactam EG 2 g - 0.2…ATCJ01CR05REGISTER NO.BE-AMP-SAM326812-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tazobactam sodiumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Piperacillin und beta-lactamase-inhibitor is registered in 12 of 19 countries.

Countries holding a registration under ATC J01CR05 (piperacillin und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search piperacillin und beta-lactamase-inhibitor products by name

Piperacillin und beta-lactamase-inhibitor · ATC J01CR05

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of piperacillin und beta-lactamase-inhibitor costs, country by country.

Normalised to the WHO defined daily dose (14 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Piperacillin und beta-lactamase-inhibitor · price per daily dose (14 g)

USD · FX 28 Sept 2026

  • CH Switzerland$158.68
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Tazobactam Sodium
Manufacturer
EG
Country
Belgium (BE)
ATC code
J01CR05
ATC class
Piperacillin und Beta-Lactamase-Inhibitor
Defined daily dose
14 g, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0792648
  • be_apb
    2572725

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

111 interactions on record for piperacillin und beta-lactamase-inhibitor.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check piperacillin und beta-lactamase-inhibitor against other medicinesHow interaction checks work

Piperacillin und beta-lactamase-inhibitor · interactions on record

111 records

  • 5 severe
  • 22 moderate
  • 4 minor
  • 80 info

Most severe, free to view

  • VancomycinA07AA09severe
  • VancomycinJ01XA01severe
  • MethotrexateL01BA01severe
  • MethotrexateL04AX03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under J01CR05

Piperacillin und beta-lactamase-inhibitor, as other registers publish it.

All piperacillin und beta-lactamase-inhibitor products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c2f616d9-e45e-4d00-a2c1-eb710d6e287b
GET /v1/drugs/c2f616d9-e45e-4d00-a2c1-eb710d6e287b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for solution for injection/infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Piperacilline-Tazobactam EG 2 g - 0.25 g",
  "name_fr": "Piperacilline-Tazobactam EG 2 g - 0.25 g",
  "name_nl": "Piperacilline-Tazobactam EG 2 g - 0.25 g",
  "amp_code": "SAM326812-00",
  "strengths": [
    "268.3000",
    "268.3000",
    "250.0000",
    "250.0000",
    "2085.0000",
    "2085.0000",
    "2000.0000",
    "2000.0000"
  ],
  "pack_count": 4,
  "substances": [
    "Tazobactam Sodium",
    "Tazobactam",
    "Piperacillin Sodium",
    "Piperacillin"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Piperacillin and Beta-Lactamase Inhibitor",
  "authorisation_numbers": [
    "BE326812"
  ]
}
API referenceMCP serverPlans

See everything about piperacillin und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console